Trial Profile

A Phase I/II Study of RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer.

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Tivozanib (Primary)
Indications Biliary cancer; Colorectal cancer; Gastric cancer; Liver cancer; Oesophageal cancer; Pancreatic cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

22 Jan 2016 Planned primary completion date changed from 1 Jun 2014 to 1 Jun 2016 as per ClinicalTrials.gov record.
14 May 2013 Planned end date changed from 1 Oct 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
02 Mar 2012 Planned end date changed from 1 Oct 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com